1. Home
  2. HOVR vs ALXO Comparison

HOVR vs ALXO Comparison

Compare HOVR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Horizon Aircraft Ltd.

HOVR

New Horizon Aircraft Ltd.

HOLD

Current Price

$1.82

Market Cap

80.5M

Sector

Finance

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.98

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOVR
ALXO
Founded
2013
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.5M
68.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HOVR
ALXO
Price
$1.82
$1.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$10.33
$3.00
AVG Volume (30 Days)
454.6K
721.1K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.41
52 Week High
$4.18
$2.66

Technical Indicators

Market Signals
Indicator
HOVR
ALXO
Relative Strength Index (RSI) 45.15 45.26
Support Level $1.70 $1.41
Resistance Level $1.90 $2.31
Average True Range (ATR) 0.15 0.19
MACD -0.01 -0.06
Stochastic Oscillator 27.14 1.45

Price Performance

Historical Comparison
HOVR
ALXO

About HOVR New Horizon Aircraft Ltd.

New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: